Pathophysiology
Using a quantitative immunostaining-TLC method, Kohriyama et al. [PMID:2435848] demonstrated that SGGLs, which react with anti-MAG antibodies, are enriched in the axolemma and present in glial-related membranes, suggesting broader targets beyond myelin in demyelinating neuropathies.
Diagnosis
Kohriyama et al. [PMID:2435848] highlight the potential importance of assessing anti-SGGL activity in patients with axonal neuropathy linked to plasma cell dyscrasias, indicating a possible diagnostic biomarker.
Differential Diagnosis
The study by Kohriyama et al. [PMID:2435848] reveals that SGGLs are present in both myelin and axonal regions, suggesting that differential diagnosis should account for potential axonal damage in patients with anti-MAG antibody-related neuropathies.
References
1 Kohriyama T, Kusunoki S, Ariga T, Yoshino JE, DeVries GH, Latov N et al.. Subcellular localization of sulfated glucuronic acid-containing glycolipids reacting with anti-myelin-associated glycoprotein antibody. Journal of neurochemistry 1987. link
1 papers cited of 3 indexed.